A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV

Journal of Virology

Volumn 87, Issue 19, 2013, Pages 10792-10804

  Turner, Tiffany M ^a   Jones, Les P ^a   Tompkins, S Mark ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; DRUG EFFICACY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84886032264     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01724-13     Document Type: Article

References (94)

1. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. 2009. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics 124:e1072-e1080.
2. Lovato-Salas F, Matienzo-Serment L, Monjaras-Avila C, Godoy-Lozano EE, Comas-Garcia A, Aguilera-Barragan M, Durham-Gonzalez A, Contreras-Vidales S, Ochoa-Perez U, Gomez-Gomez A, Garcia-Sepulveda CA, Noyola DE. 2010. Pandemic influenza A(H1N1) and respiratory syncytial virus associated hospitalizations. J. Infect. 61:382-390.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186.
5. Ropero-Alvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Andrus JK. 2009. Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 9:361. doi:10.1186/1471-2458-9-361.
6. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. 1998. Local and systemic cytokine responses during experimental human influ-enza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101:643-649.
7. Crowe JE, Jr, Williams JV. 2003. Immunology of viral respiratory tract infection in infancy. Paediatr. Respir. Rev. 4:112-119.
8. Hacking D, Hull J. 2002. Respiratory syncytial virus-viral biology and the host response. J. Infect. 45:18-24.
9. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.
10. Kalina WV, Gershwin LJ. 2004. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin. Dev. Immunol. 11:113-119.
11. Pullan CR, Hey EN. 1982. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br. Med. J. 284:1665-1669.
12. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Jr, Griffin MR. 2000. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 342:225-231.
13. Skeik N, Jabr FI. 2008. Influenza viruses and the evolution of avian influenza virus H5N1. Int. J. Infect. Dis. 12:233-238.
14. Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M, Miller MA. 2009. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N. Engl. J. Med. 361: 674-679.
15. Dawson-Caswell M, Muncie HL, Jr. 2011. Respiratory syncytial virus infection in children. Am. Fam. Physician 83:141-146.
16. Griffin MR, Coffey CS, Neuzil KM, Mitchel EF, Jr, Wright PF, Edwards KM. 2002. Winter viruses: influenza-and respiratory syncytial virusrelated morbidity in chronic lung disease. Arch. Intern. Med. 162:1229-1236.
17. Neuzil KM, Wright PF, Mitchel EF, Jr, Griffin MR. 2000. The burden of influenza illness in children with asthma and other chronic medical conditions. J. Pediatr. 137:856-864.
18. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 285:28403-28409.
19. Tripp RA. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17:165-181.
20. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 17:1132-1135.
21. Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H. 2010. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J. Virol. 84:8132-8140.
22. Shadman KA, Wald ER. 2011. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin. Biol. Ther. 11:1455-1467.
23. Sorrentino M, Powers T. 2000. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. J. 19:1068-1071.
24. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, III, Murphy BR. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSVimmunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
25. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 77:9831-9844.
26. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8:497-502.
27. Murphy BR, Walsh EE. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26:1595-1597.
28. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728.
29. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
30. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
31. Johnson TR, Varga SM, Braciale TJ, Graham BS. 2004. Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol. 78:8753-8760.
32. Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA. 2012. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and crossneutralize RSV A and B strains. Viral Immunol. 25:193-203.
33. Kim S, Chang J. 2012. Baculovirus-based vaccine displaying respiratory syncytial virus glycoprotein induces protective immunity against RSV infection without vaccine-enhanced disease. Immune Network 12:8-17.
34. Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. 2010. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J. Virol. 84:9632-9636.
35. Schepens B, Ibanez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X. 2011. Nanobodies specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J. Infect. Dis. 204:1692-1701.
36. Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA. 2010. Vaccination to induce antibodies blocking the CX3CCX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 84:1148-1157.
37. Crowe JE, Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
38. Kim HW, Arrobio JO, Brandt CD, Wright P, Hodes D, Chanock RM, Parrott RH. 1973. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52:56-63.
39. Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, Malinoski F, Hiatt PW. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:23-31.
40. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR. 2000. Evaluation of a live, cold-passaged, temperaturesensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182:1331-1342.
41. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177:467-469.
42. Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR. 1995. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 13:1095-1101.
43. Brideau RJ, Walters RR, Stier MA, Wathen MW. 1989. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein. J. Gen. Virol. 70:2637-2644.
44. Belshe RB, Anderson EL, Walsh EE. 1993. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168:1024-1029.
45. Falsey AR, Walsh EE. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15:1130-1132.
46. Munoz FM, Piedra PA, Glezen WP. 2003. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21:3465-3467.
47. Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH. 1994. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr. Infect. Dis. J. 13:792-798.
48. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
49. Polack FP, Karron RA. 2004. The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J. 23:S65-S73.
50. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. 2001. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 20:954-960.
51. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779.
52. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
53. Dormitzer PR, Rappuoli R, Casini D, O'Hagan D, Runham C, Montomoli E, Baudner B, Donnelly JJ, III, Lapini G. 2009. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr. 1:RRN1025. doi:10.1371/currents .RRN1025.
54. Subbarao K, Joseph T. 2007. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 7:267-278.
55. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3:e1401. doi:10.1371 /journal.pone.0001401.
56. Higgins DA, Carlson JR, Van Nest G. 1996. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14:478-484.
57. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216-1224.
58. Tamura S, Funato H, Nagamine T, Aizawa C, Kurata T. 1989. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 7:503-505.
59. Hunter RL. 2002. Overview of vaccine adjuvants: present and future. Vaccine 20(Suppl 3):S7-S12.
60. van Dijk H, Hofhuis FM, Berns EM, van der Meer C, Willers JM. 1980. Killed Listeria monocytogenes vaccine is protective in C3H/HeJ mice without addition of adjuvants. Nature 286:713-714.
61. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:398-401.
62. Falsey AR, Walsh EE. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14:1214-1218.
63. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. 2000. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18:1763-1772.
64. Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, Paradiso P. 1994. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 12:551-556.
65. Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL, Zaya RM. 1991. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J. Infect. Dis. 163:477-482.
66. Kilbourne ED, Schulman JL, Schild GC, Schloer G, Swanson J, Bucher D. 1971. Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J. Infect. Dis. 124:449-462.
67. Smith JH, Nagy T, Driskell E, Brooks P, Tompkins SM, Tripp RA. 2011. Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J. Virol. 85:7572-7581.
68. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162:9-14.
69. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. 1997. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. U.S.A. 94:13961-13966.
70. Vanderlinden E, Goktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L. 2010. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J. Virol. 84:4277-4288.
71. Mitchell JA, Green TD, Bright RA, Ross TM. 2003. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21:902-914.
72. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. 2009. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 22:147-161.
73. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738.
74. Smith JH, Brooks P, Johnson S, Tompkins SM, Custer KM, Haas DL, Mair R, Papania M, Tripp RA. 2011. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine 29:2568-2575.
75. Tripp RA, Sarawar SR, Doherty PC. 1995. Characteristics of the influenza virus-specific CD8+ T cell response in mice homozygous for disruption of the H-2lAb gene. J. Immunol. 155:2955-2959.
76. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL. 2011. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6:e21937. doi:10.1371/journal.pone .0021937.
77. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73:7099-7107.
78. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM. 2009. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90:1119-1123.
79. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862.
80. Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA. 2011. Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol. 24:131-142.
81. Schisler NJ, Palmer JD. 2000. The IDB and IEDB: intron sequence and evolution databases. Nucleic Acids Res. 28:181-184.
82. Li G, Siddiqui J, Hendry M, Akiyama J, Edmondson J, Brown C, Allen L, Levitt S, Poulain F, Hawgood S. 2002. Surfactant protein-A-deficient mice display an exaggerated early inflammatory response to a betaresistant strain of influenza A virus. Am. J. Respir. Cell Mol. Biol. 26:277-282.
83. Xu X, Kilbourne ED, Hall HE, Cox NJ. 1994. Nonimmunoselected intrastrain genetic variation detected in pairs of high-yielding influenza A (H3N2) vaccine and parental viruses. J. Infect. Dis. 170:1432-1438.
84. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191:1093-1104.
85. Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, Lawrence L, Zubak JJ, Chanock RM, Beeler JA, Prince GA. 1989. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7:533-540.
86. Wertz GW, Stott EJ, Young KK, Anderson K, Ball LA. 1987. Expression of the fusion protein of human respiratory syncytial virus from recombi-nant vaccinia virus vectors and protection of vaccinated mice. J. Virol. 61:293-301.
87. Crowe JE, Jr. 1995. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine 13:415-421.
88. Crowe JE, Jr, Collins PL, London WT, Chanock RM, Murphy BR. 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395-1404.
89. Walsh EE, Brandriss MW, Schlesinger JJ. 1985. Purification and characterization of the respiratory syncytial virus fusion protein. J. Gen. Virol. 66:409-415.
90. Walsh EE, Hruska J. 1983. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. 47:171-177.
91. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL. 2007. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J. Pediatr. 151:34-42, 42e1.
92. Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, Yin X. 2007. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine 25: 7422-7428.
93. Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, Graham BS. 1997. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15:525-532.
94. Aydin Z, Altunbasak Y, Pakatci IK, Erdogan H. 2007. Training set reduction methods for protein secondary structure prediction in singlesequence condition, p 5025-5028. In Conference proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society, Piscataway, NJ.